{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:09:48Z","timestamp":1790647788669,"version":"4.1.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2020,2,1]]},"DOI":"10.1001\/jamainternmed.2019.5679","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T11:31:05Z","timestamp":1574681465000},"page":"245","source":"Crossref","is-referenced-by-count":71,"title":["Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation"],"prefix":"10.1001","volume":"180","author":[{"given":"Pamela L.","family":"Lutsey","sequence":"first","affiliation":[{"name":"Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye L.","family":"Norby","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine E.","family":"Ensrud","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis"},{"name":"Center for Care Delivery and Outcomes Research, Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota"},{"name":"Department of Medicine, University of Minnesota School of Medicine, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"MacLehose","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Diem","sequence":"additional","affiliation":[{"name":"Center for Care Delivery and Outcomes Research, Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota"},{"name":"Department of Medicine, University of Minnesota School of Medicine, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota School of Medicine, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Alonso","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Department of Epidemiology, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"ioi190094r1","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1161\/CIRCULATIONAHA.117.031431","article-title":"Genetic predisposition, clinical risk factor burden, and lifetime risk of atrial fibrillation.","volume":"137","author":"Weng","year":"2018","journal-title":"Circulation"},{"issue":"7","key":"ioi190094r2","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.118.006350","article-title":"Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC study (Atherosclerosis Risk in Communities).","volume":"11","author":"Mou","year":"2018","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"8","key":"ioi190094r3","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.05.063","article-title":"Estimates of current and future incidence and prevalence of atrial fibrillation in the US adult population.","volume":"112","author":"Colilla","year":"2013","journal-title":"Am J Cardiol"},{"issue":"21","key":"ioi190094r4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"ioi190094r5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"ioi190094r6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"ioi190094r7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"ioi190094r8","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation.","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"ioi190094r9","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jjcc.2016.08.010","article-title":"Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation.","volume":"69","author":"Bengtson","year":"2017","journal-title":"J Cardiol"},{"issue":"1","key":"ioi190094r10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12872-017-0672-5","article-title":"Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.","volume":"17","author":"Norby","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"ioi190094r11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00380-017-0950-2","article-title":"Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation.","volume":"32","author":"Namba","year":"2017","journal-title":"Heart Vessels"},{"issue":"11","key":"ioi190094r12","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2017.1363","article-title":"Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation.","volume":"317","author":"Lau","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"ioi190094r13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s11606-018-4758-2","article-title":"A systematic review and meta-analysis of the association between vitamin K antagonist use and fracture.","volume":"34","author":"Fiordellisi","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"9","key":"ioi190094r14","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/jth.13052","article-title":"Vitamin K antagonists\u2019 use and fracture risk: results from a systematic review and meta-analysis.","volume":"13","author":"Veronese","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"1","key":"ioi190094r15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/jama.2017.6908","article-title":"Osteoporotic fractures associated with dabigatran vs warfarin.","volume":"318","author":"Sugiyama","year":"2017","journal-title":"JAMA"},{"key":"ioi190094r17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/pds.2317","article-title":"A systematic review of validated methods for identifying atrial fibrillation using administrative data.","volume":"21","author":"Jensen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"ioi190094r18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","article-title":"Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease.","volume":"19","author":"Hern\u00e1n","year":"2008","journal-title":"Epidemiology"},{"issue":"3","key":"ioi190094r19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/pds.v20.3","article-title":"Ascertainment of warfarin and aspirin use by medical record review compared with automated pharmacy data.","volume":"20","author":"Garg","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"ioi190094r21","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use.","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"ioi190094r22","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"2","key":"ioi190094r23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"9","key":"ioi190094r24","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/pds.v23.9","article-title":"Measuring frailty using claims data for pharmacoepidemiologic studies of mortality in older adults: evidence and recommendations.","volume":"23","author":"Kim","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"ioi190094r25","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"issue":"6","key":"ioi190094r26","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/0021-9681(66)90062-2","article-title":"Spurious effects from an extraneous variable.","volume":"19","author":"Bross","year":"1966","journal-title":"J Chronic Dis"},{"issue":"4","key":"ioi190094r27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value.","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"ioi190094r28","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","article-title":"Web Site and R package for computing E-values.","volume":"29","author":"Mathur","year":"2018","journal-title":"Epidemiology"},{"issue":"10","key":"ioi190094r29","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s00198-017-4171-4","article-title":"Adverse bone effects of medications used to treat non-skeletal disorders.","volume":"28","author":"Watts","year":"2017","journal-title":"Osteoporos Int"},{"issue":"3","key":"ioi190094r30","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00198-014-2912-1","article-title":"Warfarin use and fracture risk: an evidence-based mechanistic insight.","volume":"26","author":"Sugiyama","year":"2015","journal-title":"Osteoporos Int"},{"issue":"1","key":"ioi190094r31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1677\/JOE-07-0119","article-title":"Warfarin-induced impairment of cortical bone material quality and compensatory adaptation of cortical bone structure to mechanical stimuli.","volume":"194","author":"Sugiyama","year":"2007","journal-title":"J Endocrinol"},{"issue":"5","key":"ioi190094r32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s00774-010-0250-8","article-title":"Ultrasound bone mass in patients undergoing chronic therapy with oral anticoagulants.","volume":"29","author":"Rey-Sanchez","year":"2011","journal-title":"J Bone Miner Metab"},{"key":"ioi190094r33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbacli.2015.08.002","article-title":"Long-term warfarin therapy and biomarkers for osteoporosis and atherosclerosis.","volume":"4","author":"Namba","year":"2015","journal-title":"BBA Clin"},{"issue":"8","key":"ioi190094r34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133847","article-title":"Differential effects of dabigatran and warfarin on bone volume and structure in rats with normal renal function.","volume":"10","author":"Fusaro","year":"2015","journal-title":"PLoS One"},{"key":"ioi190094r35","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.ejim.2017.07.022","article-title":"Risk of bone fractures among users of oral anticoagulants: an administrative database cohort study.","volume":"44","author":"Lucenteforte","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"11","key":"ioi190094r36","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jacc.2016.06.034","article-title":"Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis.","volume":"68","author":"Steffel","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"ioi190094r37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archinte.166.2.241","article-title":"Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2.","volume":"166","author":"Gage","year":"2006","journal-title":"Arch Intern Med"},{"issue":"3","key":"ioi190094r38","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ijcard.2006.07.022","article-title":"Fracture risk in users of oral anticoagulants: a nationwide case-control study.","volume":"118","author":"Rejnmark","year":"2007","journal-title":"Int J Cardiol"},{"issue":"1","key":"ioi190094r39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1592\/phco.23.1.1.31922","article-title":"Warfarin therapy and risk of hip fracture among elderly patients.","volume":"23","author":"Mamdani","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"6","key":"ioi190094r40","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00198-014-2662-0","article-title":"Incident long-term warfarin use and risk of osteoporotic fractures: propensity-score matched cohort of elders with new onset atrial fibrillation.","volume":"25","author":"Misra","year":"2014","journal-title":"Osteoporos Int"},{"issue":"5","key":"ioi190094r41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1161\/CIRCOUTCOMES.113.000192","article-title":"Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.","volume":"6","author":"Zalesak","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"9319","key":"ioi190094r42","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","article-title":"Epidemiology and outcomes of osteoporotic fractures.","volume":"359","author":"Cummings","year":"2002","journal-title":"Lancet"},{"issue":"9773","key":"ioi190094r43","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: now and the future.","volume":"377","author":"Rachner","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"ioi190094r44","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/aje\/kwq111","article-title":"Linking the Iowa Women\u2019s Health Study cohort to Medicare data: linkage results and application to hip fracture.","volume":"172","author":"Virnig","year":"2010","journal-title":"Am J Epidemiol"},{"key":"ioi190094r16","unstructured":"IBM Watson Health. IBM MarketScan research databases for health services researchers (white paper). https:\/\/www.ibm.com\/downloads\/cas\/6KNYVVQ2. Published April 2019. Accessed May 2, 2019."},{"key":"ioi190094r20","unstructured":"Division of Biomedical Statistics and Informatics, Mayo Clinic Research. Biomedical Statistics and Informatics [computer program]. http:\/\/bioinformaticstools.mayo.edu\/research\/gmatch\/. Updated July 23, 2018. Accessed August 1, 2019."}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2755293\/jamainternal_lutsey_2019_oi_190094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T11:01:33Z","timestamp":1580727693000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2755293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2019.5679","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736984739.793577302","asserted-by":"object"}]},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}